NEW YORK (GenomeWeb) – Saying a recent uptick in Bruker's share price represents a less favorable risk/reward profile, investment bank ISI Group today downgraded the company's stock to a Neutral rating.

Analyst Ross Muken lowered Bruker from a previous Buy rating but raised the price target on the firm's shares to $25.50 from $24.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.